Guardant Health's 15min chart shows MACD Death Cross, KDJ Death Cross signals.
ByAinvest
Wednesday, Aug 27, 2025 3:17 pm ET1min read
GH--
The MACD (Moving Average Convergence Divergence) Death Cross occurs when the MACD line crosses below the signal line, signaling a potential change in the stock's trend. Similarly, the KDJ (Kelvin, Javits, and Divergence) Death Cross indicates a significant change in the stock's momentum, often leading to a downward trend.
Guardant Health's recent financial performance has been mixed. The company reported strong Q2 revenue of $232.1M, surpassing expectations by nearly $21M [1]. However, the company faces challenges, including a negative operating cash flow of $60.3M and a negative EBIT margin of -40.2% [1]. These financial indicators suggest that while the company is performing well in certain areas, it still faces significant operating challenges.
The company's strategic partnerships, such as the one with James Van Der Beek for a colorectal cancer campaign, have been successful in boosting awareness around their Shield blood test [1]. However, the current market sentiment surrounding Guardant Health is cautious, with concerns about the company's financial standing and potential market bubble.
Investors should closely monitor Guardant Health's stock price and technical indicators to make informed decisions. The MACD and KDJ Death Cross signals a potential downward trend, but it is essential to consider the company's overall financial performance and strategic partnerships when evaluating the stock.
References:
[1] https://stockstotrade.com/news/guardant-health-inc-gh-news-2025_08_21/
According to Guardant Health's 15-minute chart, a MACD Death Cross and KDJ Death Cross occurred on August 27, 2025 at 15:15. This indicates that the stock price has the potential to continue declining, as the momentum of the stock price is shifting towards the downside and may experience further decreases.
Guardant Health Inc. (NASDAQ: GH) has been experiencing significant market fluctuations, with a notable development on August 27, 2025, at 15:15. According to the 15-minute chart, the stock encountered a MACD Death Cross and KDJ Death Cross, indicating a potential shift in the stock's momentum towards the downside [1]. This technical indicator suggests that the stock price may continue to decline, as the momentum is changing direction.The MACD (Moving Average Convergence Divergence) Death Cross occurs when the MACD line crosses below the signal line, signaling a potential change in the stock's trend. Similarly, the KDJ (Kelvin, Javits, and Divergence) Death Cross indicates a significant change in the stock's momentum, often leading to a downward trend.
Guardant Health's recent financial performance has been mixed. The company reported strong Q2 revenue of $232.1M, surpassing expectations by nearly $21M [1]. However, the company faces challenges, including a negative operating cash flow of $60.3M and a negative EBIT margin of -40.2% [1]. These financial indicators suggest that while the company is performing well in certain areas, it still faces significant operating challenges.
The company's strategic partnerships, such as the one with James Van Der Beek for a colorectal cancer campaign, have been successful in boosting awareness around their Shield blood test [1]. However, the current market sentiment surrounding Guardant Health is cautious, with concerns about the company's financial standing and potential market bubble.
Investors should closely monitor Guardant Health's stock price and technical indicators to make informed decisions. The MACD and KDJ Death Cross signals a potential downward trend, but it is essential to consider the company's overall financial performance and strategic partnerships when evaluating the stock.
References:
[1] https://stockstotrade.com/news/guardant-health-inc-gh-news-2025_08_21/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet